PT  - JOURNAL ARTICLE
AU  - Waszczuk, Monika A.
AU  - Morozova, Olga
AU  - Lhuillier, Elizabeth
AU  - Docherty, Anna R.
AU  - Shabalin, Andrey A.
AU  - Yang, Xiaohua
AU  - Carr, Melissa A.
AU  - Clouston, Sean A. P.
AU  - Kotov, Roman
AU  - Luft, Benjamin J.
TI  - Polygenic risk scores for asthma and allergic disease associate with COVID-19 severity in 9/11 responders
AID  - 10.1101/2022.08.30.22279383
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2022.08.30.22279383
4099  - http://medrxiv.org/content/early/2023/02/16/2022.08.30.22279383.short
4100  - http://medrxiv.org/content/early/2023/02/16/2022.08.30.22279383.full
AB  - Background Genetic factors contribute to individual differences in the severity of coronavirus disease 2019 (COVID-19). A portion of genetic predisposition can be captured using polygenic risk scores (PRS). Relatively little is known about the associations between PRS and COVID-19 severity or post-acute COVID-19 in community-dwelling individuals.Methods Participants in this study were 983 World Trade Center responders infected for the first time with SARS-CoV-2 (mean age at infection=56.06; 93.4% male; 82.7% European ancestry). Seventy-five (7.6%) responders were in the severe COVID-19 category; 306 (31.1%) reported at least one post-acute COVID-19 symptom at 4-week follow-up. Analyses were adjusted for population stratification and demographic covariates.Findings The asthma PRS was associated with severe COVID-19 category (odds ratio [OR]=1.61, 95% confidence interval: 1.17-2.21) and more severe COVID-19 symptomatology (β=.09, p=.01), independently of respiratory disease diagnosis. Severe COVID-19 category was also associated with the allergic disease PRS (OR=1.97, [1.26-3.07]) and the PRS for COVID-19 hospitalization (OR=1.35, [1.01-1.82]). PRS for coronary artery disease and type II diabetes were not associated with COVID-19 severity.Conclusion Recently developed polygenic biomarkers for asthma, allergic disease, and COVID-19 hospitalization capture some of the individual differences in severity and clinical course of COVID-19 illness in a community population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by CDC/NIOSH awards U01OH012275 to Drs. Luft and Morozova, and U01OH011864 to Drs. Waszczuk and Kotov. Additional support was provided by National Institute of Health awards R01MH123619 and R01MH123489 to Drs. Docherty and Shabalin. We would like to acknowledge ongoing funding to monitor World Trade Center responders as part of the WTC Health and Wellness Program (CDC 200-2011-39361). We thank participants for their commitment to the project. The findings and conclusions in this article are those of the authors and do not represent the official position of CDC. The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Reviewer Board of Stony Brook UniversityI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData file is available at synapse.org (https://www.synapse.org/#!Synapse:syn44590167, doi:10.7303/syn44590167) and uploaded alongside the preprint on medRxiv. https://www.synapse.org/#!Synapse:syn44590167